These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 17446010)

  • 1. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.
    Lissoni P
    Pathol Biol (Paris); 2007; 55(3-4):201-4. PubMed ID: 17446010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent.
    Lissoni P
    Pathol Biol (Paris); 2007; 55(3-4):198-200. PubMed ID: 17451889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for melatonin in supportive care?
    Lissoni P
    Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
    Lissoni P; Brivio F; Fumagalli L; Messina G; Vigoré L; Parolini D; Colciago M; Rovelli F
    Anticancer Res; 2008; 28(2B):1377-81. PubMed ID: 18505083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone.
    Lissoni P; Rovelli F; Frassineti A; Fumagalli L; Malysheva O; Conti A; Maestroni G
    Neuro Endocrinol Lett; 2000; 21(4):319-323. PubMed ID: 11455367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer.
    Lissoni P; Rovelli F; Brivio F; Zago R; Colciago M; Messina G; Mora A; Porro G
    In Vivo; 2009; 23(1):171-5. PubMed ID: 19368145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients.
    Lissoni P; Malugani F; Bukovec R; Bordin V; Perego M; Mengo S; Ardizzoia A; Tancini G
    Neuro Endocrinol Lett; 2003; 24(1-2):83-5. PubMed ID: 12743539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
    Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study.
    Lissoni P; Malugani F; Brivio F; Piazza A; Vintimilla C; Giani L; Tancini G
    Neuro Endocrinol Lett; 2003; 24(3-4):259-62. PubMed ID: 14523367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
    Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ
    J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
    Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
    Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
    In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P; Bolis S; Brivio F; Fumagalli L
    Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin.
    Brackowski R; Zubelewicz B; Romanowski W; Lissoni P; Barni S; Tancini G; Maestroni GJ
    J Biol Regul Homeost Agents; 1994; 8(3):77-80. PubMed ID: 7754792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.
    Lissoni P; Barni S; Mandalà M; Ardizzoia A; Paolorossi F; Vaghi M; Longarini R; Malugani F; Tancini G
    Eur J Cancer; 1999 Nov; 35(12):1688-92. PubMed ID: 10674014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melatonin and tryptophan circadian profiles in patients with advanced non-small cell lung cancer.
    Hu S; Shen G; Yin S; Xu W; Hu B
    Adv Ther; 2009 Sep; 26(9):886-92. PubMed ID: 19802530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
    Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
    In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
    Lissoni P; Barni S; Tancini G; Brivio F; Tisi E; Zubelewicz B; Braczkowski R
    J Biol Regul Homeost Agents; 1994; 8(4):126-9. PubMed ID: 7660855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
    Lissoni P; Barni S; Tancini G; Ardizzoia A; Ricci G; Aldeghi R; Brivio F; Tisi E; Rovelli F; Rescaldani R
    Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.